RFK Jr. to Link Prenatal Tylenol Use to Autism, HHS Report Sparks Sell-Off

In Washington, U.S. Health Secretary Robert F. Kennedy Jr. said a forthcoming HHS report will tie Tylenol use during pregnancy to autism risk, sending Kenvue shares sharply lower.

In its report due this month, HHS is expected to highlight prenatal acetaminophen exposure alongside low folate levels as potential contributors to autism, underscoring growing concerns over common over-the-counter drugs.

Kennedy’s report, based on unpublished findings cited by The Wall Street Journal, will also propose the value of folinic acid supplementation in mitigating autism symptoms in some cases. Following the news, Kenvue-parent of Tylenol-maker McNeil Consumer Healthcare-saw its stock price plunge more than 6% in midday trading.

Key Points

  • HHS report to link Tylenol use during pregnancy with autism risk
  • Folinic acid recommended as a potential symptom-alleviating agent
  • Kenvue shares fell over 6% after the Journal’s report

Context and Impact

Tylenol, whose active ingredient is acetaminophen, ranks among the most widely used painkillers in the U.S., including by expectant mothers. While acetaminophen is generally regarded as safe at therapeutic doses, concerns persist over inadvertent overuse and potential neurodevelopmental effects.

McNeil and Kenvue have publicly dismissed any causal link, reiterating that “tylenol products are continuously evaluated by science, and there is no proven connection between acetaminophen taken during pregnancy and autism.”

Detailed Developments

  • Report Findings: Sources say the HHS document will focus on epidemiological data suggesting that prenatal acetaminophen exposure, particularly with inadequate maternal folate, correlates with higher autism incidence.
  • Regulatory Proposals: In addition to labeling changes, the report is expected to recommend folinic acid-a bioavailable form of folate-as an intervention to reduce autism symptoms in affected children.
  • Industry Response: Kenvue declined to comment directly but emphasized the strength of existing safety data for acetaminophen. Medical organizations continue to advise prudent use of pain relievers in pregnancy, balancing maternal comfort and fetal health.
  • Market Reaction: Investors reacted swiftly to the news, driving Kenvue’s stock down as questions mount over potential liability, labeling revisions, and consumer confidence.

Looking Ahead

The final HHS report, slated for release later this month, could prompt FDA label changes and reshape public guidance on over-the-counter pain management in pregnancy. Meanwhile, healthcare providers are poised to review prescribing practices and counsel patients on informed use of acetaminophen and folate supplementation.